论文部分内容阅读
冠状动脉粥样硬化性心脏病患者日益增多，其中有相当比例的患者接受了经皮冠状动脉介入治疗及术后双联抗血小板治疗。这些患者如果短期内需要接受非心脏手术将面临失血增加的危害，但是如果停止抗血小板治疗，围手术期支架内血栓形成的风险和心肌梗死的发生率将增加。文章针对上述问题就冠状动脉支架植入患者术后抗凝治疗的主要药物、有效性及安全性、治疗时限、并发症、围手术期抗血小板药物的停用及桥接策略等方面进行了详细阐述，以期对此类患者的围手术期安全提供帮助。“,”The number of patients with coronary atherosclerotic heart disease is increasing, and a great part of the patients undergo percutaneous coronary intervention followed by postoperative dual antiplatelet therapy. These patients will face an increasing risk of blood loss if a non-cardiac surgery is needed within a short period of time. However, once antiplatelet therapy stops, they will also face an increasing risk of perioperative stent thrombosis and myocardial infarction. This article focuses on a series of issues related to antiplatelet therapy, including common medicine, effectiveness and safety, antiplatelet therapy duration, complications, withdrawal protocol, and bridging management, in order to improve perioperative safety.